Qualigen Therapeutics Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Michael Poirier
Chief Executive Officer (CEO)
US$632.7k
Compensación total
| Porcentaje del salario del CEO | 81.0% |
| Permanencia del CEO | 7.4yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 2.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M
Aug 16Qualigen Therapeutics files mixed shelf offering of up to $150M
Jul 29Qualigen partners Hande Sciences to support its application enabling studies for QN-302
Jul 06Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?
Mar 08
We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate
Nov 23Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Deliver On Growth Plans?
Apr 05Qualigen nabs additional U.S. patent for ALAN anticancer platform
Dec 15Qualigen Therapeutics EPS misses by $0.61, misses on revenue
Nov 13Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$633k | US$513k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$18m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$728k | US$575k | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$742k | US$518k | -US$18m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$25m |
| Dec 31 2020 | US$5m | US$291k | -US$20m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$20m |
| Mar 31 2020 | n/a | n/a | -US$2m |
| Dec 31 2019 | US$252k | US$252k | -US$1m |
Compensación vs. Mercado: La compensación total ($USD632.70K) de Michael está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Michael ha sido consistente con los resultados de la empresa en el último año.
CEO
Michael Poirier (67 yo)
7.4yrs
Permanencia
US$632,698
Compensación
Mr. Michael S. Poirier serves as President and Chief Operating Officer at Qualigen Therapeutics, Inc. He has been Chief Executive Officer of Qualigen Therapeutics, Inc. (formerly known as Qualigen, Inc.) s...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7.6yrs | US$632.70k | 0.33% $ 5.9k | |
| Independent Director | 3.4yrs | US$46.00k | 0.031% $ 551.4 | |
| Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
| Independent Director | 6.9yrs | US$40.00k | 0.029% $ 504.4 | |
| Director | 4yrs | US$16.33k | 0.0064% $ 113.3 | |
| Chair of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
| Independent Director | 4yrs | US$42.00k | 0% $ 0 | |
| Independent Director | 6.9yrs | US$40.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 1.8yrs | sin datos | sin datos |
2.6yrs
Permanencia media
67yo
Promedio de edad
Junta con experiencia: La junta directiva de QLGN no se considera experimentada (2.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.